07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Poisoning Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1); PHD2 (EGLN1; HIF-PH2); PHD3 (EGLN3; HIF-PH3) Mouse studies...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Hypoxia-inducible factor prolyl hydroxylase 3 (EGLN3; HIF-PH3; PHD3) Mouse studies...
07:00 , Oct 8, 2009 |  BC Innovations  |  Targets & Mechanisms

Hitting HIF1 in cancer

Hypoxic regions in solid tumors can help trigger angiogenesis and invasion but are hard to attack with radiotherapy and chemotherapeutics because the oxygen-deprived areas are distant from any blood supply. Researchers at The Johns Hopkins...